keyword
MENU ▼
Read by QxMD icon Read
search

Y-90

keyword
https://www.readbyqxmd.com/read/28758319/treatment-options-for-unresectable-hcc-with-a-focus-on-sirt-with-yttrium-90-resin-microspheres
#1
REVIEW
Eric A Wang, Jeff P Stein, Ross J Bellavia, Scott R Broadwell
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC...
July 30, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28736649/neoadjuvant-transarterial-radiation-lobectomy-for-colorectal-hepatic-metastases-a-small-cohort-analysis-on-safety-efficacy-and-radiopathologic-correlation
#2
Jehan L Shah, Ivan R Zendejas-Ruiz, Linday M Thornton, Brian S Geller, Joseph R Grajo, Amy Collinsworth, Thomas J George, Beau Toskich
Colorectal cancer patients have a high incidence of liver metastasis (ml-CRC). Surgical resection is the gold standard for treatment of hepatic metastasis but only a small percent of patients are traditional candidates based on disease extent and adequate size of the future liver remnant (FLR). Interventions such as portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) are performed to increase FLR for operative conversion. Limitations to PVE include intrahepatic disease progression, portal vascular invasion, and utilization with concurrent chemotherapy...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28680210/incidentally-detected-thyroid-follicular-neoplasm-on-somatostatin-receptor-imaging-and-post-therapy-scan
#3
Apurva Sood, Harpreet Singh, Ashwani Sood, Rajender Kumar Basher, Bhagwant Rai Mittal
Peptide receptor radionuclide therapy (PRRT) either using Lu-177 or Y-90 peptide radiopharmaceuticals has emerged as promising treatment modality in patients with inoperable metastatic neuroendocrine tumour (NET) including medullary thyroid cancer, because of overexpression of somatostatin receptor 2 (sstr-2) on these cells. The several investigators have used PRRT in non-iodine avid differentiated thyroid cancer patients with limited success, where other treatment modalities have failed, probably due to faint sstr-2 expression in these lesions...
July 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28653161/the-post-sir-spheres-surgery-study-p4s-retrospective-analysis-of-safety-following-hepatic-resection-or-transplantation-in-patients-previously-treated-with-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres
#4
Fernando Pardo, Bruno Sangro, Rheun-Chuan Lee, Derek Manas, Rohan Jeyarajah, Vincent Donckier, Geert Maleux, Antonio D Pinna, Lourens Bester, David L Morris, David Iannitti, Pierce K Chow, Richard Stubbs, Paul J Gow, Gianluca Masi, Kevin T Fisher, Wan Y Lau, Konstantinos Kouladouros, Georgios Katsanos, Giorgio Ercolani, Fernando Rotellar, José I Bilbao, Michael Schoen
BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres(®); Sirtex)...
September 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28634672/hcc-locoregional-therapies-yttrium-90-y-90-selective-internal-radiation-therapy-sirt
#5
REVIEW
İsa Burak Güney
No abstract text is available yet for this article.
June 21, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28634669/yttrium-90-y-90-resin-microsphere-therapy-for-patients-with-unresectable-hepatocellular-carcinoma-a-single-center-experience
#6
Semra İnce, Bülent Karaman, Engin Alagoz, Nuri Karadurmuş, Hüseyin Şan, Cemal Nuri Erçin, Nuri Arslan
BACKGROUND/AIM: Selective intraarterial radionuclide therapy (SIRT) with yttrium-90 (Y-90) resin microspheres presently has successful results in primary or metastatic inoperable liver tumors. This procedure, which is also known as radioembolisation, delivers high doses of radiation selectively to hepatic tumors while minimum healthy liver exposure. The aim of this study was to present our clinical experience of radiomicrosphere therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
June 20, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28632200/the-beginning-and-development-of-the-theranostic-approach-in-nuclear-medicine-as-exemplified-by-the-radionuclide-pair-86-y-and-90-y
#7
Frank Rösch, Hans Herzog, Syed M Qaim
In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-specific and selective molecule: the "best one" for that individual patient. Transforming diagnostic imaging into quantitative dosimetric information, the optimum radioactivity (expressed in maximum radiation dose to the target tissue and tolerable dose to healthy organs) of the adequate radiotherapeutical is applied to that individual patient...
June 20, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28505506/a-methodology-for-efficiency-optimization-of-betavoltaic-cell-design-using-an-isotropic-planar-source-having-an-energy-dependent-beta-particle-distribution
#8
Sirichai Theirrattanakul, Mark Prelas
Nuclear batteries based on silicon carbide betavoltaic cells have been studied extensively in the literature. This paper describes an analysis of design parameters, which can be applied to a variety of materials, but is specific to silicon carbide. In order to optimize the interface between a beta source and silicon carbide p-n junction, it is important to account for the specific isotope, angular distribution of the beta particles from the source, the energy distribution of the source as well as the geometrical aspects of the interface between the source and the transducer...
May 5, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28480066/selective-internal-radiation-therapy-with-sir-spheres-in-hepatocellular-carcinoma-and-cholangiocarcinoma
#9
REVIEW
Eric A Wang, Scott R Broadwell, Ross J Bellavia, Jeff P Stein
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) often present at stages where patients have limited treatment options. Use of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres has progressed as data increasingly speak to its utility in patients with both intermediate and late stage disease in these cancers. In anticipation of the pending completion of several prospective randomized controlled multicenter studies exploring the use of Y-90 resin microspheres in primary liver cancers, this article outlines mechanisms involved in SIRT administration and reviews key efficacy and safety data that are currently available in the literature involving use of this therapy in both HCC and ICC...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28357572/safety-and-efficacy-of-y-90-radioembolization-after-prior-major-hepatic-resection
#10
Markus Zimmermann, Maximilian Schulze-Hagen, Martin Liebl, Federico Pedersoli, Fabian Goerg, Tom Florian Ulmer, Alexander Heinzel, Peter Isfort, Christiane Kuhl, Philipp Bruners
PURPOSE: To evaluate the safety and efficacy of yttrium-90 radioembolization (RE) following left or right hepatic lobectomy. MATERIALS AND METHODS: Between 2011 and 2016, 15 patients underwent RE with Y90-resin microspheres following right (8/15) or left (7/15) hepatic lobectomy. In eight patients, the whole liver remnant was treated during a single session, whereas the remaining seven patients received up to 3 selective RE at 1- to 2-month intervals. The administered patient activity was calculated based on the body surface area (BSA) method in all cases...
March 29, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#11
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28078375/assessing-intra-arterial-complications-of-planning-and-treatment-angiograms-for-y-90-radioembolization
#12
Osman Ahmed, Mikin V Patel, Abdulrahman Masrani, Bradford Chong, Mohammed Osman, Jordan Tasse, Jayesh Soni, Ulku Cenk Turba, Bulent Arslan
PURPOSE: To report hepatic arterial-related complications encountered during planning and treatment angiograms for radioembolization and understand any potential-associated risk factors. MATERIALS AND METHODS: 518 mapping or treatment angiograms for 180 patients with primary or metastatic disease to the liver treated by Yttrium-90 radioembolization between 2/2010 and 12/2015 were retrospectively reviewed. Intra-procedural complications were recorded per SIR guidelines...
May 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28048122/su-f-j-182-investigation-of-systems-for-improved-accuracy-in-clinical-y-90-percent-delivered-calculations
#13
R McBeth, D Elder, A Kesner
PURPOSE: Y-90 Selective Internal Radiation Therapy (SIRT) is used to treat liver tumors, and by nature has variability in the percent of the intended dose that is actually delivered. To determine the quality of the administration, pre and post activity measurements are taken, and used to infer percent delivered. Vendor specifications indicate the use of an ion chamber to take these measurements. In our work, we investigated the accuracy of ion chambers, and compared them to other detector systems...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047292/tu-fg-201-12-designing-a-risk-based-quality-assurance-program-for-a-newly-implemented-y-90-microspheres-procedure
#14
D Vile, L Zhang, L Cuttino, S Kim, J Palta
PURPOSE: To create a quality assurance program based upon a risk-based assessment of a newly implemented SirSpheres Y-90 procedure. METHODS: A process map was created for a newly implemented SirSpheres procedure at a community hospital. The process map documented each step of this collaborative procedure, as well as the roles and responsibilities of each member. From the process map, different potential failure modes were determined as well as any current controls in place...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046903/su-f-t-687-comparison-of-spect-ct-based-methodologies-for-estimating-lung-dose-from-y-90-radioembolization
#15
S Kost, S Lin, N Yu
PURPOSE: To compare mean lung dose (MLD) estimates from 99mTc macroaggregated albumin (MAA) SPECT/CT using two published methodologies for patients treated with (90) Y radioembolization for liver cancer. METHODS: MLD was estimated retrospectively using two methodologies for 40 patients from SPECT/CT images of 99mTc-MAA administered prior to radioembolization. In these two methods, lung shunt fractions (LSFs) were calculated as the ratio of scanned lung activity to the activity in the entire scan volume or to the sum of activity in the lung and liver respectively...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/27983951/trans-arterial-radioembolization-for-hepatocellular-carcinoma-who-when%C3%A2-and-y-90
#16
EDITORIAL
Neil Mehta, Francis Y Yao
No abstract text is available yet for this article.
October 27, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27875761/prognostic-value-of-post-yttrium-90-radioembolization-therapy-18f-fluorodeoxyglucose-positron-emission-tomography-in-patients-with-liver-tumors
#17
Sebastian Obrzut, Kevin McCammack, Karam W Badran, Anthony Balistreri, Evan Ou, Brian J Nguyen, Carl K Hoh, Steven C Rose
OBJECTIVE: This study assessed the benefit of post-therapy (18)F-FDG PET/CT versus CT alone in identifying malignant liver tumor progression following radioembolization with Y-90 microspheres. METHODS: 24 patients with 44 liver tumors underwent CT imaging pre-radioembolization and PET/CT post-radioembolization. Predictive value of Response Evaluation Criteria in Solid Tumors (RECIST 1.1), The World Health Organization (WHO), mRECIST and European Association for the Study of the Liver (EASL) with PET/CT versus CT alone was assessed...
March 2017: Clinical Imaging
https://www.readbyqxmd.com/read/27806615/a-volume-equivalent-spherical-necrosis-tumor-normal-liver-model-for-estimating-absorbed-dose-in-yttrium-90-microsphere-therapy
#18
Chin-Hui Wu, Yi-Jen Liao, Tzung-Yi Lin, Yu-Cheng Chen, Shung-Shung Sun, Yen-Wan Hsueh Liu, Shih-Ming Hsu
PURPOSE: Primary hepatocellular carcinoma and metastatic liver tumors are highly malignant tumors in Asia. The incidence of fatal liver cancer is also increasing in the United States. The aim of this study was to establish a spherical tumor model and determine its accuracy in predicting the absorbed dose in yttrium-90 (Y-90) microsphere therapy for liver cancer. METHODS: Liver morphology can be approximated by a spherical model comprising three concentric regions representing necrotic, tumor, and normal liver tissues...
November 2016: Medical Physics
https://www.readbyqxmd.com/read/27782730/comparison-of-quantitative-y-90-spect-and-non-time-of-flight-pet-imaging-in-post-therapy-radioembolization-of-liver-cancer
#19
COMPARATIVE STUDY
Jianting Yue, Thibault Mauxion, Diane K Reyes, Martin A Lodge, Robert F Hobbs, Xing Rong, Yinfeng Dong, Joseph M Herman, Richard L Wahl, Jean-François H Geschwind, Eric C Frey
PURPOSE: Radioembolization with yttrium-90 microspheres may be optimized with patient-specific pretherapy treatment planning. Dose verification and validation of treatment planning methods require quantitative imaging of the post-therapy distribution of yttrium-90 (Y-90). Methods for quantitative imaging of Y-90 using both bremsstrahlung SPECT and PET have previously been described. The purpose of this study was to compare the two modalities quantitatively in humans. METHODS: Calibration correction factors for both quantitative Y-90 bremsstrahlung SPECT and a non-time-of-flight PET system without compensation for prompt coincidences were developed by imaging three phantoms...
October 2016: Medical Physics
https://www.readbyqxmd.com/read/27771496/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-as-part-of-reduced-intensity-conditioning-with-melphalan-fludarabine-%C3%A2-thiotepa-for-allogeneic-transplantation-in-relapsed-or-refractory-aggressive-b-cell-lymphoma-a-geltamo-trial
#20
Monica Cabrero, Alejandro Martin, Javier Briones, Jorge Gayoso, Isidro Jarque, Javier López, Carlos Grande, Inmaculada Heras, Reyes Arranz, Teresa Bernal, Estefania Perez-Lopez, Oriana López-Godino, Eulogio Conde, Dolores Caballero
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250 mg (days -21 and -14), Y-90 ibritumomab IV (.4 m Ci/kg, day -14), fludarabine 30 mg/m(2) i.v. (days -3 and -2) plus melphalan 70 mg/m(2) i...
January 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
33440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"